Total Payments
$25,346
2024 Payments
$5,399
Companies
66
Transactions
746
Medicare Patients
1,242
Medicare Billing
$113,843
Payment Breakdown by Category
Food & Beverage$12,870 (50.8%)
Research$7,443 (29.4%)
Consulting$3,351 (13.2%)
Education$1,682 (6.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,870 | 714 | 50.8% |
| Unspecified | $7,443 | 2 | 29.4% |
| Consulting Fee | $3,351 | 3 | 13.2% |
| Education | $1,682 | 27 | 6.6% |
Payments by Type
General
$17,902
744 transactions
Research
$7,443
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $7,443 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $3,231 | 101 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,318 | 80 | $0 (2024) |
| Janssen Biotech, Inc. | $1,260 | 56 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,232 | 37 | $0 (2024) |
| Amgen Inc. | $1,167 | 42 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,106 | 54 | $0 (2024) |
| Astellas Pharma US Inc | $584.26 | 21 | $0 (2024) |
| PFIZER INC. | $561.28 | 40 | $0 (2024) |
| Daiichi Sankyo Inc. | $490.39 | 32 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,399 | 178 | Novartis Pharmaceuticals Corporation ($2,157) |
| 2023 | $10,898 | 108 | Eli Lilly and Company ($7,443) |
| 2022 | $1,155 | 55 | Amgen Inc. ($169.82) |
| 2021 | $696.03 | 38 | Pharmacyclics LLC, An AbbVie Company ($132.79) |
| 2020 | $1,088 | 47 | Amgen Inc. ($220.26) |
| 2019 | $2,458 | 110 | E.R. Squibb & Sons, L.L.C. ($340.62) |
| 2018 | $2,467 | 142 | E.R. Squibb & Sons, L.L.C. ($258.41) |
| 2017 | $1,183 | 68 | Novartis Pharmaceuticals Corporation ($212.34) |
All Payment Transactions
746 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $26.27 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: Oncology | ||||||
| 12/17/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), YONSA | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: HORMONE THERAPY | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: Immunology | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: Oncology | ||||||
| 12/08/2024 | BeiGene USA, Inc. | BRUKINSA (Drug), TEVIMBRA | Food and Beverage | In-kind items and services | $167.51 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.81 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.29 | General |
| Category: Oncology | ||||||
| 11/26/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $0.14 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $25.21 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $10.06 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: Oncology | ||||||
| 11/05/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/31/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.83 | General |
| Category: Hematology/Oncology | ||||||
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.89 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | Eli Lilly and Company | $7,443 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 217 | 413 | $48,749 | $20,962 |
| 2022 | 4 | 199 | 470 | $50,481 | $23,342 |
| 2021 | 6 | 349 | 689 | $75,108 | $34,285 |
| 2020 | 8 | 477 | 1,022 | $95,595 | $35,255 |
Total Patients
1,242
Total Services
2,594
Medicare Billing
$113,843
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 158 | 345 | $36,225 | $15,576 | 43.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 40 | 49 | $7,546 | $3,584 | 47.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $4,978 | $1,801 | 36.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 155 | 419 | $43,995 | $20,831 | 47.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 17 | 19 | $2,926 | $1,374 | 47.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 14 | 14 | $2,198 | $599.60 | 27.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 18 | $1,362 | $537.06 | 39.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 203 | 473 | $49,665 | $23,550 | 47.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 48 | 58 | $8,932 | $4,400 | 49.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 34 | 94 | $6,862 | $2,480 | 36.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 34 | 34 | $5,338 | $2,148 | 40.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 13 | 13 | $3,172 | $1,371 | 43.2% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 17 | 17 | $1,139 | $334.80 | 29.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 228 | 634 | $63,560 | $23,594 | 37.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 59 | 144 | $10,512 | $4,381 | 41.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 46 | 70 | $10,378 | $4,080 | 39.3% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 21 | 21 | $3,178 | $1,124 | 35.4% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Facility | 2020 | 21 | 21 | $2,163 | $799.06 | 36.9% |
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Facility | 2020 | 77 | 107 | $4,173 | $782.02 | 18.7% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 13 | 13 | $851.00 | $265.05 | 31.1% |
| 99201 | New patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 12 | 12 | $780.00 | $230.23 | 29.5% |
About Dr. Christopher Croot, MD
Dr. Christopher Croot, MD is a Hematology & Oncology healthcare provider based in Pikeville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1053318717.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Croot, MD has received a total of $25,346 in payments from pharmaceutical and medical device companies, with $5,399 received in 2024. These payments were reported across 746 transactions from 66 companies. The most common payment nature is "Food and Beverage" ($12,870).
As a Medicare-enrolled provider, Croot has provided services to 1,242 Medicare beneficiaries, totaling 2,594 services with total Medicare billing of $113,843. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Pikeville, KY
- Active Since 07/07/2005
- Last Updated 09/22/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1053318717
Products in Payments
- SCEMBLIX (Drug) $1,863
- OPDIVO (Biological) $1,197
- KEYTRUDA (Biological) $993.21
- CALQUENCE (Drug) $582.55
- DARZALEX (Biological) $568.69
- KISQALI (Drug) $547.02
- IMBRUVICA (Drug) $496.36
- Enhertu (Drug) $300.60
- XTANDI (Drug) $242.19
- ZEJULA (Drug) $237.82
- ERLEADA (Drug) $223.28
- BRUKINSA (Drug) $219.05
- TAGRISSO (Drug) $206.47
- Imbruvica (Drug) $204.28
- LIBTAYO (Biological) $203.26
- Kyprolis (Biological) $201.87
- VYXEOS (Drug) $197.45
- Abraxane (Drug) $191.39
- ZEPZELCA (Drug) $175.90
- LYNPARZA (Drug) $159.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.